Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) is a multinational healthcare company known for its diversified portfolio of pharmaceuticals, medical devices, and consumer health products. Founded in 1886, it has established itself as a leading player in healthcare, with a global presence and a reputation for innovation and quality in the industry.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 9, 2025 | $1.30 | 2025-08-26 | 2025-08-26 |
| June 10, 2025 | $1.30 | 2025-05-27 | 2025-05-27 |
| March 4, 2025 | $1.24 | 2025-02-18 | 2025-02-18 |
| December 10, 2024 | $1.24 | 2024-11-26 | 2024-11-26 |
| September 10, 2024 | $1.24 | 2024-08-27 | 2024-08-27 |
Dividends Summary
- Johnson & Johnson has issued 87 dividend payments over the past 21 years
- The most recent dividend was paid 28 days ago, on September 9, 2025
- The highest dividend payed out to investors during this period was $1.30 per share
- The average dividend paid during this period was $0.74 per share.
Company News
The diffuse cutaneous systemic sclerosis (dcSSc) market is evolving towards targeted therapies addressing fibrosis and immune modulation, with promising drug candidates from multiple pharmaceutical companies targeting various pathogenic pathways.
Pfizer surged after striking a landmark agreement with the Trump administration to lower drug prices and expand U.S. production, securing a three-year tariff exemption and committing to $70 billion in U.S. manufacturing investments.
Jabil demonstrates strong Q4 2025 performance with 18.5% revenue growth, benefiting from AI and tech sector strengths in capital equipment, data center, and networking markets. The company shows robust financial health with favorable guidance and potential for significant stock price appreciation.
Johnson & Johnson reported promising clinical trial results for a new multiple myeloma treatment combination, with 100% patient response and 85.7% achieving complete response in newly diagnosed patients.
This week, J&J and Novartis reported strong Q2 earnings, while Roche's investigational oral weight loss drug showed positive results in an early-stage study. AbbVie also filed for approval of its drug Rinvoq for a new indication.
